In our study, we found that 9.5% (4/42) of VAFIDH was higher than the maximum VAF of coalteration trunk driver genes (VAFIDH–VAFmax [EGFR/ALK/KRAS/BRAF] > 0.01), which was lower than the expected VAF for IDH active‐site mutations, indicating that they were likely subclonal evolution of branching drivers of lung adenocarcinoma. This evidence concerns the gene BRAF and lung adenocarcinoma.